CTOs on the Move

Cenegenics

www.cenegenics.com

 
Get a personalized medical team of experts that tests for and treats the earliest signs and avoidable symptoms associated with chronic disease and aging.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cenegenics.com
  • 851, South Rampart Boulevard
    Las Vegas, NV USA 89145
  • Phone: 702.953.1583

Executives

Name Title Contact Details

Similar Companies

AppliedVR

AppliedVR is the leader in therapeutic virtual reality, transforming healthcare through the power of pixels. Since its founding in 2015, appliedVR has delivered scientifically designed and validated digital health solutions to over 20,000 patients in more than 250 hospitals and in 8 countries globally.

Med-Health Medical Supplies

Med-Health Medical Supplies is a North Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Care Management Group

Health Care Management Group is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bethesda, MD. To find more information about Health Care Management Group, please visit www.hcmg.net

EnWave Corporation

EnWave Corporation is a Prince George, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.